UK markets closed

BNTX Jan 2025 160.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.00000.0000 (0.00%)
At close: 03:10PM EDT
Full screen
Previous close1.0000
Open1.0000
Bid0.7000
Ask1.1000
Strike160.00
Expiry date2025-01-17
Day's range1.0000 - 1.0000
Contract rangeN/A
Volume1
Open interest41
  • Barrons.com

    This Vaccine Maker Sits on Cash Almost Equal to Its Market Value

    This biotechnology company has nearly 90% of its market value in cash and investments but is being shunned by investors even as they gravitate to the sector this year. The company is BioNTech (Ticker BNTX). It partnered with Pfizer to produce the leading Covid vaccine, Comirnaty, whose original messenger RNA technology was developed by BioNTech.

  • Reuters

    UPDATE 2-BioNTech gets US agency notice over default on COVID vaccine royalties

    BioNTech said on Monday the U.S. National Institutes of Health has sent a notice to the German company regarding default on the payment of royalties and other amounts related to its COVID-19 vaccine. BioNTech, which partnered with U.S. pharma giant Pfizer for its COVID-19 vaccine, however, said it disagreed with the positions being taken by the NIH and intends to defend against all allegations of breach. Spokespersons for the U.S. NIH did not immediately respond to Reuters' request for a comment.

  • Simply Wall St.

    BioNTech Full Year 2023 Earnings: Misses Expectations

    BioNTech ( NASDAQ:BNTX ) Full Year 2023 Results Key Financial Results Revenue: €3.82b (down 78% from FY 2022). Net...